Abstract
Tau aggregation is an appealing target for therapeutic intervention. However, conformational change or aggregation needs to be targeted without inhibiting the normal biology of tau and its role in microtubule stabilization. The number of compound classes being tested at this time are very limited and include Congo red derivatives [1], anthraquinones (Pickhardt et al. 2005 [2], disputed in Crowe et al. 2007 [3]), 2,3-di(furan-2-yl)-quinoxalines , phenylthiazolyl-hydrazide (PTH) [4], polyphenols and porphyrins [5] and cyanine dyes [6-8]. Herein we have utilized a member of the cyanine dye family (C11) in an organotypic slice culture model of tangle formation. Our results demonstrate that C11 is capable of affecting tau polymerization in a biphasic, dose dependent manner. At submicromolar concentrations (0.001 μM) C11 reduced levels of aggregated tau. However, higher doses resulted in an increase in tau polymerization. These effects can also be seen at the level of individual filaments with changes in filament length and number mirroring the pattern seen via immunoblotting. In addition, this effect is achieved without altering levels of phosphorylation at disease and microtubule binding relevant epitopes.
Keywords: Alzheimer disease, tau, tangle, cyanine, phosphorylation, polymerization
Current Alzheimer Research
Title: Disaggregation of Tau as a Therapeutic Approach to Tauopathies
Volume: 7 Issue: 3
Author(s): K. Duff, J. Kuret and E.E Congdon
Affiliation:
Keywords: Alzheimer disease, tau, tangle, cyanine, phosphorylation, polymerization
Abstract: Tau aggregation is an appealing target for therapeutic intervention. However, conformational change or aggregation needs to be targeted without inhibiting the normal biology of tau and its role in microtubule stabilization. The number of compound classes being tested at this time are very limited and include Congo red derivatives [1], anthraquinones (Pickhardt et al. 2005 [2], disputed in Crowe et al. 2007 [3]), 2,3-di(furan-2-yl)-quinoxalines , phenylthiazolyl-hydrazide (PTH) [4], polyphenols and porphyrins [5] and cyanine dyes [6-8]. Herein we have utilized a member of the cyanine dye family (C11) in an organotypic slice culture model of tangle formation. Our results demonstrate that C11 is capable of affecting tau polymerization in a biphasic, dose dependent manner. At submicromolar concentrations (0.001 μM) C11 reduced levels of aggregated tau. However, higher doses resulted in an increase in tau polymerization. These effects can also be seen at the level of individual filaments with changes in filament length and number mirroring the pattern seen via immunoblotting. In addition, this effect is achieved without altering levels of phosphorylation at disease and microtubule binding relevant epitopes.
Export Options
About this article
Cite this article as:
Duff K., Kuret J. and Congdon E.E, Disaggregation of Tau as a Therapeutic Approach to Tauopathies, Current Alzheimer Research 2010; 7(3) . https://dx.doi.org/10.2174/156720510791050885
DOI https://dx.doi.org/10.2174/156720510791050885 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Prodrug Strategy for Enhancing Drug Delivery via Skin
Current Drug Discovery Technologies Soy Isoflavones and Cardiovascular Health: An Update
Current Nutrition & Food Science Understanding Borderline Personality Disorder Across Sociocultural Groups: Findings, Issues, and Future Directions
Current Psychiatry Reviews Inflammation in Alzheimer’s Disease
Current Alzheimer Research Therapeutic Advancement in Alzheimer Disease: New Hopes on the Horizon?
CNS & Neurological Disorders - Drug Targets Neuroprotective Effects of Citrus Fruit-Derived Flavonoids, Nobiletin and Tangeretin in Alzheimer's and Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Zinc-mediated Neurotransmission in Alzheimer's Disease: A Potential Role of the GPR39 in Dementia
Current Neuropharmacology Repurposing of Copper(II)-chelating Drugs for the Treatment of Neurodegenerative Diseases
Current Medicinal Chemistry Is there a Link between Vitamin B and Multiple Sclerosis?
Medicinal Chemistry The CNS Melanocortin System: A Biological Weapon Against the Threat of Obesity
Current Medicinal Chemistry - Central Nervous System Agents The Dynamics of the Hypothalamic-Pituitary-Ovarian Axis, ReproductivePerformance and Sexuality Following Bariatric Surgery
Current Women`s Health Reviews Potential Crossreactivity of Human Immune Responses Against HCMV Glycoprotein B
Current Drug Discovery Technologies Regulating miRNA by Natural Agents as a New Strategy for Cancer Treatment
Current Drug Targets GHB – Induced Cognitive Deficits During Adolescence and the Role of NMDA Receptor
Current Neuropharmacology Nicotine and Nicotinic Receptor Involvement in Neuropsychiatric Disorders
Current Topics in Medicinal Chemistry Nanotechnology in Personalized Medicine: A Promising Tool for Alzheimer’s Disease Treatment
Current Medicinal Chemistry Non-Analgesic Effects of Opioids: Opioids and the Endocrine System
Current Pharmaceutical Design Start Small and Stay Small: Minimizing Attrition in the Clinic with a Focus on CNS Therapeutics
Current Topics in Medicinal Chemistry Reactions, Anti-Alzheimer and Anti COX-2 Activities of 6-Pyridin-3-yl-1Hpyrazolo[ 3,4-b]pyridin-3-amines
Current Organic Chemistry Proteomics and Epigenetic Mechanisms in Stem Cells
Current Proteomics